Researchers in China have been experimenting with using blood plasma from patients who have recovered from COVID-19 as a possible way to treat severely ill COVID-19 patients. In a new study published in the Proceedings of the National Academy of Science, clinicians reported that convalescent plasma therapy improved the outcomes of ten patients with severe cases of COVID-19.
“It’s consistent with what I’m hearing from other places,” Michael Joyner, a physiologist at Mayo Clinic who is leading a convalescent plasma clinical trial in the US and wasn’t involved in the study from China, told The Wire Science.
In convalescent plasma therapy, a dose of antibody-containing plasma obtained from the blood of recovered individuals is transferred to persons with the disease in order to treat it. It’s an experimental therapy going back a hundred years, having found use – to different efficacies – in the treatment of the Spanish flu as well as, more recently, the 2009 H1N1 influenza, SARS and MERS viruses.
Convalescent plasma could shorten the duration of a COVID-19 illness or render it less dangerous. The therapy can be administered at different stages: after exposure to a known carrier but before infection to boost immunity, and to critically and non-critically ill patients to improve their outcomes.
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.